---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Access and distribution"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Access and distribution. Topics: Commercial launch readiness: sales force, medical affairs, and brand preparation, November 2026; Payer engagement before approval; Anticipated coverage at launch: commercial plans first, Medicare through the exception process; Patient support program; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial launch readiness: sales force, medical affairs, and brand preparation, November 2026

> “The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place. The Company continues to engage with leading hypertension experts and payers. Brand marketing preparations are well underway, and the Company is finalizing a full-service patient support program designed to ease access for physicians, their office staff and patients.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “From an execution standpoint, I am pleased to report that our field sales team is now in place. In addition to our seasoned commercial leadership team, we have hired sales representatives with an average industry tenure of approximately 15 years.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-2"></a>

### Payer engagement before approval

> “On the market access front, our engagement with payers now extends to the majority of U.S. covered lives. Our discussions continue to center on the clinical and economic burden of uncontrolled hypertension and the value proposition supported by lorundrostat's clinical data package.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

> “An experienced commercial leadership team is now in place, initial sales territories and priority geographies have been identified, and engagement continues with leading hypertension experts and payers covering a substantial majority of U.S. lives.”

Source: [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026)

> “The team was engaging Medicare as well as commercial payers. I will say we are on their radar. They are very well aligned with the positioning that John spoke of, and we are now in the midst of scheduling these pre-approval information exchange, or PIE, discussions.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.11-3"></a>

### Anticipated coverage at launch: commercial plans first, Medicare through the exception process

> “So from a payer coverage perspective, Rami, so definitely commercial will lead the way in terms of providing that access or that coverage initially. But we will, and we do anticipate Medicare coverage through the exception process, as I mentioned on a prior response. The Medicare exception process typically looks at the label, but it does require some navigation of that in which the PSP that we put forward is designed to support that.”
> “We've gotten questions in the past about missing the bid cycle as AstraZeneca did. Presuming we get approved, we won't hit that bid cycle as well, whether or not patients on Medicare will get access.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-4"></a>

### Patient support program

> “In parallel, we are finalizing a full-service patient support program designed to help physicians, their office staff and patients navigate access efficiently.”
> “In terms of timing, so shortly after launch, you can anticipate that patient support program.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.11-5"></a>

### Target prescribers: about 60,000 physicians, 60% primary care and 40% specialty

> “As you have heard us say before, when we look at where we have developed this molecule, third line or later, and in the United States who prescribes there, it is about 60,000 physicians that are responsible for half of the scripts third line or later.”
> “It is about a 60/40 split, primary care/specialty, the bulk of the specialty being cardiologists.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.11-6"></a>

### Manufacturing by third-party contract manufacturers

> “We do not own or operate manufacturing facilities for the production of lorundrostat, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently depend on third-party contract manufacturers for our required raw materials, active pharmaceutical ingredients, and finished product candidates for our clinical trials.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or limited distribution network

No evidence found.

<a id="topic-2.1.2.11-8"></a>

### Sales, marketing, and distribution strategy not yet defined, March 2026, superseded in August 2026

> “We have not yet defined our sales, marketing, or product distribution strategy for lorundrostat because it is still in clinical development and pending regulatory approval. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or the establishment of our own commercial sales force.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
